{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:55:30Z","timestamp":1761947730176,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015503","name":"Fonds d'Etudes et de Recherche du Corps Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015503","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejca.2025.116024","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:25:54Z","timestamp":1759008354000},"page":"116024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-1664","authenticated-orcid":false,"given":"Adrien","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-8795","authenticated-orcid":false,"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-4723","authenticated-orcid":false,"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-4315","authenticated-orcid":false,"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ronchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Berdah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-3302","authenticated-orcid":false,"given":"Gabriel","family":"Kacso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Calabro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Tartas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Muracciole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Ribault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116024_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The european cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.116024_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10336","key":"10.1016\/j.ejca.2025.116024_bib3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (Peace-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"10467","key":"10.1016\/j.ejca.2025.116024_bib4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (Peace-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.ejca.2025.116024_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.116024_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.116024_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"7","key":"10.1016\/j.ejca.2025.116024_bib8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","article-title":"Adjusting for the confounding effects of treatment Switching\u2014The BREAK-3 trial: dabrafenib versus dacarbazine","volume":"20","author":"Latimer","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2025.116024_bib9","first-page":"388","article-title":"Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting","volume":"23","author":"Sullivan","year":"2020","journal-title":"Value Health J Int Soc Pharm Outcomes Res"},{"issue":"10","key":"10.1016\/j.ejca.2025.116024_bib10","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1177\/0962280220912524","article-title":"Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding","volume":"29","author":"Latimer","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"10.1016\/j.ejca.2025.116024_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","article-title":"Methods for adjusting for bias due to crossover in oncology trials","volume":"32","author":"Ishak","year":"2014","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.ejca.2025.116024_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.32614\/RJ-2017-068","article-title":"Rpsftm: an r package for rank preserving structural failure time models","volume":"9","author":"Allison","year":"2017","journal-title":"R J"},{"key":"10.1016\/j.ejca.2025.116024_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2019.103339","article-title":"Ipcwswitch: an r package for inverse probability of censoring weighting with an application to switches in clinical trials","volume":"111","author":"Graff\u00e9o","year":"2019","journal-title":"Comput Biol Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.116024_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11523-019-00685-x","article-title":"Adjusting overall survival estimates for treatment switching in metastatic, Castration-Sensitive prostate cancer: results from the LATITUDE study","volume":"14","author":"Feyerabend","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2025.116024_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euros.2021.11.012","article-title":"Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study","volume":"36","author":"Koroki","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"36","key":"10.1016\/j.ejca.2025.116024_bib16","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with Androgen-Deprivation therapy in patients with metastatic Hormone-Sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:51:25Z","timestamp":1761947485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925006100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"alternative-id":["S0959804925006100"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116024"}}